Login to Your Account



Advanced Ocular Systems Gains IP For Anti-VEGFs

By Randall Osborne


Tuesday, February 21, 2006
Following up the merger with Australia-based Regenera Ltd. in a $31 million deal, Advanced Ocular Systems Ltd. broadened its intellectual property base by acquiring patent applications that, if granted, could cover the ocular use of anti-VEGF agents such as Genentech Inc.’s Avastin. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription